Companies / Q32 Bio Inc.
Q32 Bio Inc.
Nasdaq: QTTBCIK 1661998WALTHAM, MA
Insider flow · last 90 daysNet buys $15.00M
Financials · FY2025
Ownership
29.8M shares outstanding · as of Aug 3, 2026
Ownership
| Insiders | 2.71% | 805,616 |
| 10%+ / strategic | 4.22% | 1,256,228 |
| Institutions | 16.33% | 4,862,012 |
| Public float | 76.74% | 22,845,610 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 10
View all →| Insider | % of shares | Shares |
|---|---|---|
Orbimed Advisors LLCDirector · 10% owner | 2.10% | 625,000 |
Morrison Jodie PopeCEOCEO · Director | 0.30% | 89,104 |
Violette Shelia M.Chief Scientific Officer | 0.19% | 55,569 |
Kalowski LeeCFO and President | 0.12% | 35,943 |
Grayzel David S.Director | — | — |
Laporte KathleenDirector | — | — |
Lundberg Sven AnteDirector | — | — |
OrbiMed Capital GP VII LLCDirector · 10% owner | — | — |
OrbiMed Genesis GP LLCDirector · 10% owner | — | — |
Thistle MaryDirector | — | — |
Institutional holders 57
View all →| Holder | Value | % of shares |
|---|---|---|
| $14.46M | 7.57% | |
| $6.95M | 7.03% | |
| $2.06M | 1.08% | |
| $1.64M | 1.66% | |
| $1.57M | 0.82% | |
| $1.51M | 0.40% | |
| $1.33M | 0.70% | |
| $1.07M | 1.08% | |
| $922.2K | 0.93% | |
| $769.0K | 0.20% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q2 2026 as of | Carlyle Group Inc. 13F manager | Trim | Common stock | $-13.28M | -1.0M -94.53% | 60,363 0.20% of shares | medium |
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | Common stock | $746.2K | +59K +97.74% | 118,507 0.40% of shares | low |
| Q1 2026 as of | Renaissance Technologies LLC 13F manager | Add | Common stock | $689.0K | +107K +107.75% | 206,915 0.70% of shares | low |
| Q2 2026 as of | Quadrature Capital Ltd 13F manager | New | Common stock | $463.7K | +36K | 36,396 0.12% of shares | low |
| Q2 2026 as of | State Street Corporation 13F manager | Add | Common stock | $394.6K | +31K +145.86% | 52,214 0.18% of shares | low |
| Q1 2026 as of | Marshall Wace, LLP 13F manager | New | Common stock | $336.7K | +52K | 52,440 0.18% of shares | low |
| Q3 2024 as of | Barclays PLC 13F manager | Add | Common stock | $238.9K | +5K +105.17% | 10,443 0.04% of shares | low |
| Q2 2026 as of | LPL Financial LLC 13F manager | New | Common stock | $231.5K | +18K | 18,170 0.06% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Opaleye Management Inc. | Passive13G | — |
| Point72 Asset Management, L.P. | Passive13G | — |
| Pfizer Inc | Passive13G/A | — |
| RA Capital Management, L.P. | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| QTTB | — | 746964105 |